Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) EBT (2016 - 2025)

Ptc Therapeutics has reported EBT over the past 14 years, most recently at -$1.4 billion for Q4 2025.

  • Quarterly results put EBT at -$1.4 billion for Q4 2025, down 1366.65% from a year ago — trailing twelve months through Dec 2025 was -$553.2 million (down 52.35% YoY), and the annual figure for FY2025 was -$553.2 million, down 52.35%.
  • EBT for Q4 2025 was -$1.4 billion at Ptc Therapeutics, down from -$23.1 million in the prior quarter.
  • Over the last five years, EBT for PTCT hit a ceiling of $929.8 million in Q1 2025 and a floor of -$1.4 billion in Q4 2025.
  • Median EBT over the past 5 years was -$119.9 million (2021), compared with a mean of -$72.3 million.
  • Peak annual rise in EBT hit 1197.84% in 2025, while the deepest fall reached 1366.65% in 2025.
  • Ptc Therapeutics' EBT stood at $349.1 million in 2021, then plummeted by 154.33% to -$189.7 million in 2022, then soared by 430.9% to $627.7 million in 2023, then crashed by 115.09% to -$94.7 million in 2024, then tumbled by 1366.65% to -$1.4 billion in 2025.
  • The last three reported values for EBT were -$1.4 billion (Q4 2025), -$23.1 million (Q3 2025), and -$71.1 million (Q2 2025) per Business Quant data.